Comparative Pharmacology
Head-to-head clinical analysis: TURQOZ versus TZ 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TURQOZ versus TZ 3.
TURQOZ vs TZ-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TURQOZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
400 mg orally once daily.
100 mg orally twice daily
None Documented
None Documented
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Primarily renal (80% unchanged) with 10% fecal, 5% biliary, 5% other
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Category C
Category C
Unknown
Unknown